BIIB021 (CNF2024) is a potent, fully synthetic, and orally bioavailable HSP90 inhibitor with a Ki of 1.7 nM and an EC50 of 38 nM. This small molecule is a valuable research tool for studying HSP90s role in oncology and neurodegenerative diseases, demonstrating activity in both cellular and animal models of cancer.